The thesis

BDSX is a diagnostic solutions provider with 34.2% revenue growth, but a -27.0% net margin. The Decifer score is 12, indicating dormancy. Analyst consensus is BUY, despite a -10.0x P/E ratio and a DCF intrinsic value of -$255. High gross margins of 82.5% suggest potential for profitability.

Why now

The recent Nasdaq gains and ISM manufacturing PMI slip in September create a risk-off environment, but BDSX's strong revenue growth could be a catalyst for re-evaluation. The USA Unemployment Rate increase to 4.2% in September may also impact investor sentiment.

What to watch

Investors should watch BDSX's next quarter revenue growth and net margin to confirm if the company is on a path to profitability. The upcoming earnings reports and any changes in analyst consensus ratings will also be crucial indicators.

Key risks

The negative net margin and high valuation risk due to a -10.0x P/E ratio could invalidate the thesis. Execution risk is also high, as the company needs to improve its profitability.

Theme exposure